Analysts’ Opinions Are Mixed on These Healthcare Stocks: Viridian Therapeutics (VRDN), Biodesix (BDSX) and Staar Surgical (STAA)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viridian Therapeutics (VRDN – Research Report), Biodesix (BDSX – Research Report) and Staar Surgical (STAA – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Viridian Therapeutics (VRDN)
In a report released today, Serge Belanger from Needham maintained a Buy rating on Viridian Therapeutics, with a price target of $42.00. The company’s shares closed last Friday at $27.90.
According to TipRanks.com, Belanger is a 5-star analyst with an average return of
Viridian Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $41.86, implying a 45.5% upside from current levels. In a report issued on February 2, Wedbush also maintained a Buy rating on the stock with a $47.00 price target.
See the top stocks recommended by analysts >>
Biodesix (BDSX)
In a report released today, Kyle Mikson CFA from Canaccord Genuity reiterated a Buy rating on Biodesix, with a price target of $20.00. The company’s shares closed last Friday at $11.45.
According to TipRanks.com, CFA is a 3-star analyst with an average return of
Currently, the analyst consensus on Biodesix is a Strong Buy with an average price target of $30.00.
Staar Surgical (STAA)
Piper Sandler analyst Adam Maeder maintained a Hold rating on Staar Surgical today and set a price target of $16.00. The company’s shares closed last Friday at $16.10, close to its 52-week low of $13.50.
According to TipRanks.com, Maeder is a 5-star analyst with an average return of
Staar Surgical has an analyst consensus of Hold, with a price target consensus of $21.13, a 27.9% upside from current levels. In a report issued on February 3, Wedbush also initiated coverage with a Hold rating on the stock with a $26.00 price target.
